Betibeglogene Autotemcel Gene Therapy for Non-β
Adolescent
Adult
Biological Products
/ adverse effects
Busulfan
/ therapeutic use
Child
Erythrocyte Transfusion
/ adverse effects
Erythropoiesis
Female
Genetic Therapy
/ methods
Genetic Vectors
Genotype
Hemoglobins
/ analysis
Humans
Iron Overload
/ prevention & control
Lentivirus
/ genetics
Male
Middle Aged
Myeloablative Agonists
/ therapeutic use
beta-Globins
/ genetics
beta-Thalassemia
/ blood
Journal
The New England journal of medicine
ISSN: 1533-4406
Titre abrégé: N Engl J Med
Pays: United States
ID NLM: 0255562
Informations de publication
Date de publication:
03 02 2022
03 02 2022
Historique:
pubmed:
11
12
2021
medline:
17
2
2022
entrez:
10
12
2021
Statut:
ppublish
Résumé
Betibeglogene autotemcel (beti-cel) gene therapy for transfusion-dependent β-thalassemia contains autologous CD34+ hematopoietic stem cells and progenitor cells transduced with the BB305 lentiviral vector encoding the β-globin (β In this open-label, phase 3 study, we evaluated the efficacy and safety of beti-cel in adult and pediatric patients with transfusion-dependent β-thalassemia and a non-β A total of 23 patients were enrolled and received treatment, with a median follow-up of 29.5 months (range, 13.0 to 48.2). Transfusion independence occurred in 20 of 22 patients who could be evaluated (91%), including 6 of 7 patients (86%) who were younger than 12 years of age. The average hemoglobin level during transfusion independence was 11.7 g per deciliter (range, 9.5 to 12.8). Twelve months after beti-cel infusion, the median level of gene therapy-derived adult hemoglobin (HbA) with a T87Q amino acid substitution (HbA Treatment with beti-cel resulted in a sustained HbA
Sections du résumé
BACKGROUND
Betibeglogene autotemcel (beti-cel) gene therapy for transfusion-dependent β-thalassemia contains autologous CD34+ hematopoietic stem cells and progenitor cells transduced with the BB305 lentiviral vector encoding the β-globin (β
METHODS
In this open-label, phase 3 study, we evaluated the efficacy and safety of beti-cel in adult and pediatric patients with transfusion-dependent β-thalassemia and a non-β
RESULTS
A total of 23 patients were enrolled and received treatment, with a median follow-up of 29.5 months (range, 13.0 to 48.2). Transfusion independence occurred in 20 of 22 patients who could be evaluated (91%), including 6 of 7 patients (86%) who were younger than 12 years of age. The average hemoglobin level during transfusion independence was 11.7 g per deciliter (range, 9.5 to 12.8). Twelve months after beti-cel infusion, the median level of gene therapy-derived adult hemoglobin (HbA) with a T87Q amino acid substitution (HbA
CONCLUSIONS
Treatment with beti-cel resulted in a sustained HbA
Identifiants
pubmed: 34891223
doi: 10.1056/NEJMoa2113206
doi:
Substances chimiques
Biological Products
0
Hemoglobins
0
Myeloablative Agonists
0
beta-Globins
0
betibeglogene autotemcel
0
Busulfan
G1LN9045DK
Banques de données
ClinicalTrials.gov
['NCT02906202']
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
415-427Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Massachusetts Medical Society.